06 aprile 2021 13:02
Fonte: Adnkronos
#salute-e-benessere
Simple, Non-Invasive Blood Test Poses No Risk to Pregnant Woman and Fetus; Significantly Safer, More Comprehensive and More Inclusive Compared to Invasive Tissue Sampling Test
Intended for All Pregnant Women, Not Just High-Risk Categories, at 10-14 Weeks of Pregnancy; Earlier Administration Potentially Leading to Higher Confidence and More Individualized Care
Achievement Follows ARCEDI s Prior Non-Invasive Pregnancy Testing Innovations, Including Being the First Company to Identify Extravillous Trophoblasts as the Fetal Cell Types Circulating Within the Maternal Bloodstream
VEJLE, Denmark, April 6, 2021 /PRNewswire/ ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced the launch of EVITA TEST COMPLETE™ (EVITA), the first prenatal genetic blood test to identify and isolate fetal cells in maternal blood. EVITA provides a comple
ARCEDI Biotech Announces Availability of EVITA TEST COMPLETE™ First Prenatal Genetic Blood Test to Identify and Isolate Fetal Cells in Maternal Blood
Simple, Non-Invasive Blood Test Poses No Risk to Pregnant Woman and Fetus; Significantly Safer, More Comprehensive and More Inclusive Compared to Invasive Tissue Sampling Test
Intended for All Pregnant Women, Not Just High-Risk Categories, at 10-14 Weeks of Pregnancy; Earlier Administration Potentially Leading to Higher Confidence and More Individualized Care
Achievement Follows ARCEDI s Prior Non-Invasive Pregnancy Testing Innovations, Including Being the First Company to Identify Extravillous Trophoblasts as the Fetal Cell Types Circulating Within the Maternal Bloodstream
News provided by
ARCEDI Biotech Announces Availability of EVITA TEST COMPLETE First Prenatal Genetic Blood Test to Identify and Isolate Fetal Cells in Maternal Blood finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.